SU5416 in Treating Children With Recurrent or Progressive Brain Tumors
Stopped early · Phase 1
Conditions studied: Brain and Central Nervous System Tumors
In brief
RATIONALE: SU5416 may stop the growth of brain cancer cells by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the safety of delivering SU5416 in children who have recurrent or progressive brain tumors.
Key facts
- Study ID
- NCT00006247
- Run by
- Pediatric Brain Tumor Consortium
- People needed
- 33
- Starts
- 2000-08-01
- Expected to finish
- 2006-03-01
- Last updated by the study team
- 2009-10-14
Who can join
Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCSF Cancer Center and Cancer Research Institute — San Francisco, California, United States
- Children's National Medical Center — Washington D.C., District of Columbia, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- Duke Comprehensive Cancer Center — Durham, North Carolina, United States
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
- Children's Hospital of Pittsburgh — Pittsburgh, Pennsylvania, United States
- Saint Jude Children's Research Hospital — Memphis, Tennessee, United States
- Baylor College of Medicine — Houston, Texas, United States
- Children's Hospital and Regional Medical Center - Seattle — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.